Valuation: Pacific Biosciences of California, Inc.

Capitalization 713M 611M 569M 530M 989M 64.32B 1.07B 6.54B 2.57B 30.77B 2.67B 2.62B 113B P/E ratio 2025 *
-1.28x
P/E ratio 2026 * -4.27x
Enterprise value 1.08B 926M 862M 802M 1.5B 97.39B 1.61B 9.91B 3.9B 46.59B 4.05B 3.96B 171B EV / Sales 2025 *
6.85x
EV / Sales 2026 * 6.63x
Free-Float
90.66%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
01-12 Pacific Biosciences of California, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 10:30 AM
01-12 Pacific Biosciences to Collaborate With n-Lorem, EspeRare on Genetic Therapies MT
01-12 PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases CI
01-12 Pacbio announces preliminary fourth quarter and full year 2025 revenue RE
01-12 PacBio HiFi Announces it has Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood CI
01-08 PacBio and UC Davis Researchers Introduce CiFi, A New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from A Single SMRT Cell CI
11-06 Pacific Biosciences of California, Inc., Q3 2025 Earnings Call, Nov 05, 2025
11-05 PacBio Q3 revenue falls to $38.4 mln, EPS beats RE
11-05 Pacific Biosciences of California, Inc. Narrows Earnings Guidance for the Full Year 2025 CI
11-05 Pacific Biosciences of California, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-04 PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China CI
14/10/25 Pacific Biosciences of California, Inc. Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities CI
13/10/25 Pacbio Announces Its Hifi Sequencing Technology Has Been Selected as the Primary Platform for the Korean Pangenome Reference Project CI
More news
1 day+10.80%
1 week+10.80%
Current month+26.20%
1 month+11.32%
3 months+48.43%
6 months+61.64%
Current year+26.20%
More quotes
1 week 1.84
Extreme 1.84
2.37
1 month 1.67
Extreme 1.67
2.37
Current year 1.79
Extreme 1.79
2.37
1 year 0.85
Extreme 0.8511
2.72
3 years 0.85
Extreme 0.8511
14.55
5 years 0.85
Extreme 0.8511
53.69
10 years 0.85
Extreme 0.8511
53.69
More quotes
Manager TitleAgeSince
Chief Executive Officer 58 13/09/2020
Chief Tech/Sci/R&D Officer 58 31/12/2003
Director of Finance/CFO 57 30/03/2025
Director TitleAgeSince
Director/Board Member 67 31/12/2003
Director/Board Member 72 31/12/2008
Director/Board Member 69 17/01/2012
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+10.80%+10.80%+27.57%-78.47% 643M
+2.43%+0.76%+11.64%+6.51% 228B
-2.68%-7.68%+1.46%+111.19% 199B
+1.01%+1.01%+0.14%-13.04% 166B
-0.42%-4.98%-2.00%+101.46% 140B
+0.66%+2.06%-7.27%-5.56% 60.69B
-0.88%-2.04%+16.98%+6.12% 48.65B
-0.27%-1.28%+1.74%-7.01% 41.48B
+0.63%-0.54%+1.39%+30.35% 38.61B
+1.90%+4.55%+13.41%+18.99% 37.1B
Average +1.32%+0.22%+6.51%+17.05% 96.04B
Weighted average by Cap. +0.23%-1.86%+3.87%+38.65%
See all sector performances

Financials

2025 *2026 *
Net sales 157M 135M 126M 117M 218M 14.21B 235M 1.45B 569M 6.8B 590M 578M 24.91B 178M 153M 142M 133M 247M 16.09B 267M 1.64B 644M 7.7B 669M 655M 28.21B
Net income -551M -473M -441M -410M -765M -49.78B -825M -5.06B -1.99B -23.81B -2.07B -2.03B -87.25B -170M -146M -136M -126M -236M -15.36B -254M -1.56B -615M -7.35B -638M -625M -26.92B
Net Debt 366M 314M 293M 272M 508M 33.07B 548M 3.36B 1.32B 15.82B 1.37B 1.35B 57.96B 469M 402M 375M 349M 651M 42.33B 701M 4.31B 1.69B 20.25B 1.76B 1.72B 74.19B
More financial data * Estimated data
Logo Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Employees
575
More about the company
Date Price Change Volume
14/01/26 2.360 $ +10.80% 11,628,897
13/01/26 2.130 $ +5.97% 9,399,128
12/01/26 2.010 $ +3.61% 10,723,423
09/01/26 1.940 $ -4.90% 11,465,618
08/01/26 2.040 $ -4.23% 6,793,555

Delayed Quote Nasdaq, January 14, 2026 at 09:00 pm

More quotes
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
2.360USD
Average target price
2.417USD
Spread / Average Target
+2.40%
Consensus

Quarterly revenue - Rate of surprise